Arena BioWorks, launched in 2024 with $500 million funding from high-profile billionaires, has appointed biotech veteran Harvey Berger as its new CEO. Berger reunites with co-founder Stuart Schreiber, now chief scientific officer. The leadership change comes amid organizational restructuring, including significant staff reductions. Berger brings experience from ARIAD Pharmaceuticals, leading it through its first drug approval, and aims to guide Arena toward focused scientific and commercial success amidst a competitive biotech environment.